Golimumab for the treatment of ankylosing spondylitis

24 August 2011

The British Society for Rheumatology (BSR) welcomes the guidance from National Institute of Health and Clinical Excellence (NICE) on the use of Golimumab for patients with ankylosing spondylitis.

Dr Ian Rowe, Chair of BSR Clinical Affairs Committee said; “We are very pleased that NICE has given positive guidance on the use of Golimumab for patients with ankylosing spondylitis. This offers patients with ankylosing spondylitis the opportunity to get this new treatment and benefit from the advantages it may have. It also allows clinicians more options to treat patients, enabling the treatment of this disease to be more effective.”